Manufacturing, Specialty Dosage Forms

Tapemark, a full-service CDMO specializing in transdermal, oral thin film, and topical drug-delivery technologies, is exhibiting at CPhI.

The agency publishes draft guidance on assessing the adhesion of transdermal delivery systems and topical patches.

Curida entered into a partnership with René Bommer, PhD, founder and owner of pharmAccel Consulting.

Quality by design, in-vitro release testing, and modern analytical methods are improving understanding and control of these complex formulations.

Advances in transdermal drug delivery, particularly with microneedles, are enabling a wider range of drugs to be delivered through the skin.

Mylan completes expansion of its transdermal patch facility in Vermont.

New studies reveal the promise and feasibility of transdermal vaccine delivery.

Private companies and universities are developing new ways to deliver protein drugs.

In a draft guidance published this week, the US Food and Drug Administration recommended that makers of transdermal and transmucosal drug-delivery systems use "an appropriate scientific approach" during product design, development, and manufacturing to minimize the amount of residual drug substance present at the end of the products' labeled use periods.

If you’ve worked in the drug industry for a while, chances are good that you remember Pfizer’s Rezulin, which was produced through hot melt extrusion (HME). If you work for a major pharmaceutical manufacturer, it’s likely that your company owns a twin-screw extruder. Yet HME has not been a common way of manufacturing drugs, and many industry employees don’t understand the principles of HME or the advantages that the technique offers.

Instead of hampering progress, cost pressures might inspire Big Pharma to get creative.

A microelectronic system based on radio-frequency (RF) cell ablation addresses limitations of other transdermal drug-delivery methods. This system expands the transdermal spectrum to include the delivery of water-soluble molecules, peptides, proteins, and other macromolecules.

Transdermal delivery takes up once-forbidden compounds, reviving markets and creating formulation opportunities.

Transdermal drug technology specialists are meeting demands for methods that can painlessly deliver larger molecules in therapeutic quantities.

Adhesives manufacturers can be involved in the development of transdermal drug delivery products by working with pharmaceutical companies on R&D, materials qualification, manufacturing, and other product development tasks.